<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4">Chlamydia trachomatis</h1><h4 class="text-base font-semibold mt-4 mb-2"><strong>2015 UK BASHH Guideline for the Management of Chlamydia trachomatis Genital Infection1. Scope &amp; Key Updates</strong></h4><ul><li>Applies to patients ≥16 y seen in UK Level-3 STI services; principles adaptable to all settings.</li><li>2015 revisions highlight: NAAT/POCT use, repeat-testing advice, azithromycin efficacy debate, management of rectal infection, pregnancy/neonate issues. </li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>2. Epidemiology &amp; Aetiology</strong></h4><ul><li><em>C. trachomatis</em> serovars D–K cause urogenital disease; L1–L3 cause LGV.</li><li>Most common curable bacterial STI in UK – &gt;208 000 cases (2013); 70 % in 15-24 y.</li><li>Prevalence 1.5–4.3 % in general population surveys; higher (5–10 %) in specific studies.</li><li>Risk factors: &lt;25 y, new/multiple partners, inconsistent condom use.</li><li>Up to 75 % partner concordance; up to 50 % spontaneous clearance at 12 months.</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>3. Clinical Presentation</strong></h4><table><tr><td><p><strong>Site</strong></p></td><td><p><strong>Symptoms</strong></p></td><td><p><strong>Signs</strong></p></td><td><p><strong>Complications</strong></p></td></tr><tr><td><p><strong>Women</strong></p></td><td><p>discharge, PCB/IMB, dysuria, pelvic pain, dyspareunia</p></td><td><p>mucopurulent cervicitis, pelvic tenderness</p></td><td><p>PID (≤ 16 %), infertility, ectopic, perihepatitis, SARA</p></td></tr><tr><td><p><strong>Men</strong></p></td><td><p>urethral discharge, dysuria (often mild)</p></td><td><p>urethral discharge</p></td><td><p>epididymo-orchitis, SARA</p></td></tr><tr><td><p><strong>Rectum</strong></p></td><td><p>usually asymptomatic; may have discharge, discomfort</p></td><td><p>–</p></td><td><p>proctitis, LGV</p></td></tr><tr><td><p><strong>Pharynx</strong></p></td><td><p>usually silent</p></td><td><p>–</p></td><td><p>–</p></td></tr><tr><td><p><strong>Conjunctiva</strong></p></td><td><p>chronic unilateral irritation</p></td><td><p>–</p></td><td><p>–</p></td></tr></table><h4 class="text-base font-semibold mt-4 mb-2"><strong>4. Diagnosis</strong></h4><h5><strong>4.1 Preferred Assay</strong></h5><ul><li><strong>NAATs</strong> – highest sensitivity/specificity for genital &amp; extra-genital sites. No routine requirement for dual-platform confirmation except medico-legal cases.</li></ul><h5><strong>4.2 Optimal Specimens</strong></h5><ul><li><strong>Women</strong>: self- or clinician-taken vulvo-vaginal swab (VVS) – sensitivity 96–98 % (preferred to endocervical or urine).</li><li><strong>Men</strong>: first-catch urine (FCU) equal/ superior to urethral swab.</li><li><strong>Rectum / Pharynx</strong>: NAAT on swab; blind or proctoscopic rectal sampling acceptable.</li><li><strong>LGV testing</strong>: all patients with proctitis and all HIV-positive MSM with CT at any site. Samples sent to PHE STBRU.</li></ul><h5><strong>4.3 Practical Points</strong></h5><ul><li>Window: if exposure &lt;14 days, test now and repeat at 2 weeks.</li><li>Inhibition controls desirable; be aware of nvCT deletion issue (assays now redesigned).</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>5. Management</strong></h4><h5><strong>5.1 General</strong></h5><ul><li>No need to remove IUD/IUS for uncomplicated infection.</li><li>Abstain from all sexual contact (including oral) until both partners treated (+7 d after azithro).</li><li>Offer full STI screen incl. HIV; vaccinate/test for HBV where indicated. Provide written info.</li></ul><h5><strong>5.2 Recommended Regimens</strong></h5><table><tr><td><p><strong>Clinical Scenario</strong></p></td><td><p><strong>First-line</strong></p></td><td><p><strong>Alternatives / Notes</strong></p></td></tr><tr><td><p><strong>Uncomplicated genital or pharyngeal CT</strong></p></td><td><p>Doxycycline 100 mg bd × 7 d <strong>or</strong> Azithromycin 1 g stat</p></td><td><p>Ofloxacin 200 mg bd × 7 d or Erythromycin 500 mg bd 10–14 d if contraindications</p></td></tr><tr><td><p><strong>Rectal CT (non-LGV)</strong></p></td><td><p><strong>Doxycycline 100 mg bd × 7 d</strong> (preferred)</p></td><td><p>Azithromycin 1 g stat (perform TOC or give longer doxy if LGV not excluded)</p></td></tr><tr><td><p><strong>Pregnancy / Breast-feeding</strong></p></td><td><p>Azithromycin 1 g stat (safe &amp; effective)</p></td><td><p>Erythro 500 mg qds × 7 d, Erythro 500 mg bd × 14 d, or Amoxicillin 500 mg tds × 7 d; avoid doxy/ofloxacin</p></td></tr><tr><td><p><strong>Gonorrhoea + CT</strong></p></td><td><p>Usual GC therapy (ceftriaxone 500 mg IM + azithro 1 g) covers CT; if rectal CT/LGV, still add doxy 100 mg bd × 7–21 d</p></td><td></td></tr><tr><td><p><strong>HIV-positive</strong></p></td><td><p>Same regimens; if rectal CT without LGV result, treat 3 w doxy or TOC</p></td><td></td></tr></table><h5><strong>5.3 Adverse-effect pearls</strong></h5><ul><li>Doxycycline – GI upset, photosensitivity, oesophagitis (take with water; remain upright).</li><li>Azithromycin – GI upset, potential QT prolongation.</li><li>Erythromycin – high GI intolerance; avoid in cholestatic liver disease.</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>6. Test of Cure (TOC) &amp; Retesting</strong></h4><ul><li><strong>TOC not routine</strong> – residual DNA up to 5 wks. Indicated in pregnancy, suspected non-adherence, persistent symptoms or where LGV cannot be excluded (rectal infection treated with 1 g azithro/7 d doxy).</li><li>Perform ≥3 wks after completion.</li><li><strong>Repeat screening</strong>: all positive patients &lt;25 y – offer test at 3 months (reinfection 10–30 %). Insufficient evidence for routine &gt;25 y unless high risk.</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>7. Partner Notification</strong></h4><ul><li>Look-back:<ul><li>Symptomatic males (urethral): contacts since, and 4 wks prior to, symptom onset.</li><li>All others (women, asymptomatic men, rectal/pharyngeal cases): contacts in prior 6 months.</li></ul></li><li>Offer epidemiological treatment to all contacts; document PN outcomes within 4 wks.</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>8. Pregnancy &amp; Neonate</strong></h4><ul><li>Vertical transmission → conjunctivitis (5–12 d) or pneumonia (1–3 m).</li><li>Treat infant: <strong>Erythromycin 50 mg/kg/day PO ÷4 doses × 14 d</strong> (oral preferred; topical insufficient).</li><li>Test &amp; treat mother + partners; schedule TOC ≥3 wks post-therapy.</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>9. Point-of-Care Testing (POCT)</strong></h4><ul><li>Older EIA POCTs insensitive; newer NAAT-based POCTs emerging – comparable accuracy + rapid turnaround, but extra-genital validation ongoing.</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>10. Exam-Focused Take-Home Messages</strong></h4><ol><li><strong>Doxy 7 d vs. Azithro 1 g</strong> – equivalent for genital CT, but doxy preferred for rectal disease.</li><li><strong>Vulvo-vaginal swab</strong> is the best sample in women; urine acceptable but less sensitive.</li><li><strong>LGV testing</strong> mandatory in proctitis &amp; HIV-positive MSM with CT; treat 3 w doxy if unsure.</li><li><strong>TOC</strong> only when clinically indicated; always ≥3 weeks post-therapy.</li><li><strong>Repeat test at 3 months in &lt;25 y</strong> – high reinfection risk &amp; PID prevention.</li><li><strong>Pregnancy</strong> – azithro single dose is safe; avoid tetracyclines/fluoroquinolones.</li><li><strong>Partner management &amp; risk reduction counselling</strong> are central – document actions.</li></ol><h2 class="text-xl font-semibold mt-6 mb-3"><strong>A. Extra details you may want to add to your <em>Chlamydia trachomatis</em> notes</strong></h2><ol><li><strong>Self-sampling acceptability</strong> – multiple studies show good uptake and diagnostic performance for self-taken rectal &amp; pharyngeal swabs in both sexes, supporting home-based or nurse-free testing pathways. bashh_chlamydia</li><li><strong>Medico-legal cases</strong> – take NAATs from <em>all</em> penetrated sites; confirm a positive with a second NAAT target/platform because of evidential standards. bashh_chlamydia</li><li><strong>Auditable outcomes</strong> – BASHH expects ≥97 % documentation of partner-action plans, LGV serovar confirmation (where relevant) and correct SHHAPT coding; keep this in mind for quality-improvement OSPE questions.</li></ol><table><tr><td><p><strong>Theme</strong></p></td><td><p><strong>Extra detail in guideline</strong></p></td><td><p><strong>Citation</strong></p></td></tr><tr><td><p><strong>What’s new in 2015</strong></p></td><td><p>Guideline highlights six changes (NAAT + POCT use, advice on repeat testing, debate over 1 g azithro, co-treating gonorrhoea, rectal infection therapy, vertical transmission/neonate care).</p></td><td></td></tr><tr><td><p><strong>Sampling – practical pearls</strong></p></td><td><p>▸ <em>Inhibition control</em>: labs should know whether their NAAT includes one, as inhibitors give false-negatives. ▸ <em>Female FCU</em>: less sensitive than VVS; if used, collect <strong>first 20 ml after ≥1 h void abstinence</strong>.</p></td><td></td></tr><tr><td><p><strong>Point-of-care NAAT</strong></p></td><td><p>New-generation NAAT-based POCTs reach ≈82–84 % sens. vs lab NAAT and look cost-effective; EIA-based POCT no longer acceptable.</p></td><td></td></tr><tr><td><p><strong>Medico-legal testing</strong></p></td><td><p>Positive NAAT must be <strong>confirmed on a second genetic target</strong>; culture no longer recommended.</p></td><td></td></tr><tr><td><p><strong>General management advice</strong></p></td><td><p>Chlamydia is <em>not</em> an indication to remove an IUD/IUS; treatment should be &gt;95 % effective, ≤bd dosing, low side-effect.</p></td><td></td></tr><tr><td><p><strong>Broader STI screen &amp; vaccination</strong></p></td><td><p>Offer HIV (repeat if in window), and hepatitis B screen/vaccine to all index cases and contacts.</p></td><td></td></tr><tr><td><p><strong>Risk-reduction counselling</strong></p></td><td><p>One-to-one, theory-based discussion at/after treatment; complex cases referred to PN-trained staff; evidence grade A.</p></td><td></td></tr><tr><td><p><strong>Partner-notification follow-up</strong></p></td><td><p>PN outcome for each contact should be documented <strong>within 4 weeks</strong> of first discussion.</p></td><td></td></tr><tr><td><p><strong>Auditable outcome measures</strong></p></td><td><p>Four ≥97 % targets: correct therapy, LGV testing on reactive rectals, written patient info given, PN documented per BASHH.</p></td><td></td></tr><tr><td><p><strong>Acceptability of self-taken extragenital swabs</strong></p></td><td><p>Multiple studies show good performance &amp; patient acceptability for self-collected rectal/pharyngeal swabs in MSM.</p></td><td></td></tr><tr><td><p><strong>Natural history facts</strong> (exam fodder)</p></td><td><p>Up to <strong>50 %</strong> untreated infections clear spontaneously by ~12 months; transmission concordance ≤75 %.</p></td><td></td></tr></table>
</div>